OCULAR THERAPEUTIX, INC Cash and Restricted Cash
OCULAR THERAPEUTIX, INC (OCUL) had Cash and Restricted Cash of $600.25 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $600.25M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $668.31M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $738.67M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $346.39M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $600.25M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $668.31M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $738.67M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $346.39M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $392.75M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $351.30M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $393.72M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $428.83M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $461.30M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $484.65M 10-Q · filed 2025-05-05 |
| 2023-12-31 | $197.57M 10-K · filed 2026-02-05 |
| 2023-09-30 | $112.31M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $68.37M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $80.79M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $104.06M 10-K · filed 2026-02-05 |
| 2022-09-30 | $122.71M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $136.30M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $147.18M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $165.93M 10-K · filed 2025-03-03 |
| 2021-09-30 | $181.04M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $193.62M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $211.14M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $229.82M 10-K · filed 2024-03-11 |
| 2020-09-30 | $72.41M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $86.06M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $49.92M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $56.20M 10-K · filed 2023-03-06 |
| 2019-09-30 | $67.18M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $68.53M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $82.86M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $60.68M 10-K · filed 2022-02-28 |
| 2018-09-30 | $58.48M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $58.45M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $64.53M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $43.15M 10-K · filed 2020-03-12 |
| 2017-09-30 | $52.89M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $64.78M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $56.41M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $34.66M 10-K · filed 2020-03-12 |
| 2015-12-31 | $31.01M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |